Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 3/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29726801 | 0.83 | NOS2 (0.52) | NPC1RAB9ASMN1; SMN2HTTPDE4A | |
| SCHEMBL22708268 | 0.80 | MEN1 (0.40) | NPC1SMN1; SMN2HTTCES2CES1 | |
| SCHEMBL4319151 | 0.78 | MAPT (0.54) | NPC1RAB9ASMN1; SMN2HTTPDE4A | |
| SCHEMBL30437267 | 0.76 | POLB (0.38) | ALDH1A1LMNAMAPTMEN1KMT2A | |
| SCHEMBL18545986 | 0.75 | HPGD (0.67) | NPC1RAB9ASMN1; SMN2HTTPDE4A | |
| SCHEMBL21220132 | 0.74 | CES2 (0.64) | NPC1RAB9ASMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL18346348 | 0.74 | CES2 (0.64) | NPC1RAB9ASMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL2008961 | 0.74 | CES2 (0.64) | NPC1RAB9ASMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL28561525 | 0.73 | ALDH1A1 (0.49) | NPC1RAB9ASMN1; SMN2HTTPDE4A | |
| SCHEMBL12304002 | 0.73 | CES2 (0.58) | NPC1RAB9ASMN1; SMN2PDE4APDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345665-B2 | Chiral 1,3-diarylimidazolium salt carbene precursor, synthesis method therefor, metal salt compound and application thereof | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2022-05-31 | — | — | US | disclosed |
| US-11345665-B2 | Chiral 1,3-diarylimidazolium salt carbene precursor, synthesis method therefor, metal salt compound and application thereof | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2022-05-31 | — | — | US | disclosed |
| US-20200369620-A1 | CHIRAL 1,3-DIARYLIMIDAZOLIUM SALT CARBENE PRECURSOR, SYNTHESIS METHOD THEREFOR, METAL SALT COMPOUND AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369620-A1 | CHIRAL 1,3-DIARYLIMIDAZOLIUM SALT CARBENE PRECURSOR, SYNTHESIS METHOD THEREFOR, METAL SALT COMPOUND AND APPLICATION THEREOF | CYP51A1, SLC39A11, ZC3HAV1L | NPC1 1444/4885RAB9A 3818/4885SMN1; SMN2 2549/4885 |
| US-11345665-B2 | Chiral 1,3-diarylimidazolium salt carbene precursor, synthesis method therefor, metal salt compound and application thereof | CYP51A1, SLC39A11, ZC3HAV1L | NPC1 1444/4885RAB9A 3818/4885SMN1; SMN2 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.